Janus Henderson Group PLC Trims Position in argenex SE $ARGX

Janus Henderson Group PLC lowered its stake in shares of argenex SE (NASDAQ:ARGX) by 4.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,458,164 shares of the company’s stock after selling 117,087 shares during the period. argenex makes up approximately 0.9% of Janus Henderson Group PLC’s portfolio, making the stock its 13th biggest holding. Janus Henderson Group PLC owned approximately 3.97% of argenex worth $2,057,856,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of ARGX. AQR Capital Management LLC raised its stake in argenex by 32.1% during the first quarter. AQR Capital Management LLC now owns 502 shares of the company’s stock worth $297,000 after purchasing an additional 122 shares during the period. NewEdge Advisors LLC raised its stake in argenex by 5,962.5% during the first quarter. NewEdge Advisors LLC now owns 1,455 shares of the company’s stock worth $862,000 after purchasing an additional 1,431 shares during the period. Focus Partners Wealth raised its stake in argenex by 22.3% during the first quarter. Focus Partners Wealth now owns 400 shares of the company’s stock worth $237,000 after purchasing an additional 73 shares during the period. Geneos Wealth Management Inc. raised its stake in argenex by 550.0% during the first quarter. Geneos Wealth Management Inc. now owns 117 shares of the company’s stock worth $69,000 after purchasing an additional 99 shares during the period. Finally, Northwestern Mutual Wealth Management Co. raised its stake in argenex by 60.2% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 133 shares of the company’s stock worth $73,000 after purchasing an additional 50 shares during the period. Hedge funds and other institutional investors own 60.32% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. Guggenheim increased their price target on shares of argenex from $1,120.00 to $1,135.00 and gave the stock a “buy” rating in a research note on Friday, May 8th. Robert W. Baird increased their price target on shares of argenex from $858.00 to $867.00 and gave the stock a “neutral” rating in a research note on Friday, February 27th. Zacks Research raised shares of argenex from a “strong sell” rating to a “hold” rating in a research note on Friday, February 20th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of argenex in a research note on Monday, April 20th. Finally, Royal Bank Of Canada dropped their price objective on shares of argenex from $925.00 to $890.00 and set an “outperform” rating for the company in a research report on Friday, February 27th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, argenex has an average rating of “Moderate Buy” and a consensus price target of $1,019.50.

argenex Stock Up 1.6%

argenex stock opened at $892.26 on Thursday. argenex SE has a 52-week low of $510.05 and a 52-week high of $934.62. The firm has a fifty day moving average of $820.36 and a 200-day moving average of $810.81. The firm has a market capitalization of $55.49 billion, a P/E ratio of 39.73, a PEG ratio of 1.34 and a beta of 0.47.

argenex (NASDAQ:ARGX) last released its quarterly earnings data on Tuesday, March 31st. The company reported $5.52 earnings per share (EPS) for the quarter. argenex had a net margin of 31.31% and a return on equity of 44.37%. The company had revenue of $1.31 billion during the quarter. On average, research analysts expect that argenex SE will post 26.19 EPS for the current fiscal year.

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.